SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Castel D)
 

Search: WFRF:(Castel D) > Diffuse intrinsic p...

Diffuse intrinsic pontine gliomas (DIPG) at recurrence : is there a window to test new therapies in some patients?

Lobon-Iglesias, M. J. (author)
Gustave Roussy, Dept Pediat & Adolescent Oncol, Villejuif, France.;Univ Paris Saclay, Villejuif, France.;CNRS, Unite Mixte Rech 8203, Team Target Identificat & Innovat Anticanc Therap, Villejuif, France.
Giraud, Geraldine (author)
Uppsala universitet,Science for Life Laboratory, SciLifeLab,Neuroonkologi,Gustave Roussy, Dept Pediat & Adolescent Oncol, Villejuif, France.;Univ Paris Saclay, Villejuif, France
Castel, D. (author)
Gustave Roussy, Dept Pediat & Adolescent Oncol, Villejuif, France.;Univ Paris Saclay, Villejuif, France.;CNRS, Unite Mixte Rech 8203, Team Target Identificat & Innovat Anticanc Therap, Villejuif, France.
show more...
Philippe, C. (author)
Univ Paris Saclay, Villejuif, France.;CNRS, Unite Mixte Rech 8203, Team Target Identificat & Innovat Anticanc Therap, Villejuif, France.
Debily, M. A. (author)
Univ Paris Saclay, Villejuif, France.;CNRS, Unite Mixte Rech 8203, Team Target Identificat & Innovat Anticanc Therap, Villejuif, France.;Univ Evry Val dEssone, Evry, France.
Briandet, C. (author)
Univ Hosp Dijon, Dept Pediat, Dijon, France.
Fouyssac, F. (author)
Univ Hosp Nancy Brabois, Dept Pediat Oncol, Nancy, France.
de Carli, E. (author)
Univ Hosp Angers, Dept Pediat Oncol, Angers, France.
Dufour, C. (author)
Gustave Roussy, Dept Pediat & Adolescent Oncol, Villejuif, France.;Univ Paris Saclay, Villejuif, France.;CNRS, Unite Mixte Rech 8203, Team Target Identificat & Innovat Anticanc Therap, Villejuif, France.
Valteau-Couanet, D. (author)
Gustave Roussy, Dept Pediat & Adolescent Oncol, Villejuif, France.;Univ Paris Saclay, Villejuif, France.
Sainte-Rose, C. (author)
Necker Sick Childrens Univ Hosp, Dept Neurosurg, Paris, France.;Paris Descartes Univ, Paris, France.
Blauwblomme, T. (author)
Necker Sick Childrens Univ Hosp, Dept Neurosurg, Paris, France.;Paris Descartes Univ, Paris, France.
Beccaria, K. (author)
Univ Paris Saclay, Villejuif, France.;CNRS, Unite Mixte Rech 8203, Team Target Identificat & Innovat Anticanc Therap, Villejuif, France.;Necker Sick Childrens Univ Hosp, Dept Neurosurg, Paris, France.;Paris Descartes Univ, Paris, France.
Zerah, M. (author)
Necker Sick Childrens Univ Hosp, Dept Neurosurg, Paris, France.;Paris Descartes Univ, Paris, France.
Puget, S. (author)
Necker Sick Childrens Univ Hosp, Dept Neurosurg, Paris, France.;Paris Descartes Univ, Paris, France.
Calmon, R. (author)
Paris Descartes Univ, Paris, France.;Necker Sick Childrens Univ Hosp, Dept Radiol, Paris, France.;Imagine Inst, Paris, France.;INSERM, U1163, Paris, France.
Boddaert, N. (author)
Paris Descartes Univ, Paris, France.;Necker Sick Childrens Univ Hosp, Dept Radiol, Paris, France.;Imagine Inst, Paris, France.;INSERM, U1163, Paris, France.
Bolle, S. (author)
Gustave Roussy, Dept Radiotherapy, Villejuif, France.
Varlet, P. (author)
Paris Descartes Univ, Paris, France.;St Anne Hosp, Dept Neuropathol, Paris, France.
Grill, J. (author)
Gustave Roussy, Dept Pediat & Adolescent Oncol, Villejuif, France.;Univ Paris Saclay, Villejuif, France.;CNRS, Unite Mixte Rech 8203, Team Target Identificat & Innovat Anticanc Therap, Villejuif, France.
show less...
Gustave Roussy, Dept Pediat & Adolescent Oncol, Villejuif, France;Univ Paris Saclay, Villejuif, France.;CNRS, Unite Mixte Rech 8203, Team Target Identificat & Innovat Anticanc Therap, Villejuif, France. Science for Life Laboratory, SciLifeLab (creator_code:org_t)
2017-12-02
2018
English.
In: Journal of Neuro-Oncology. - : SPRINGER. - 0167-594X .- 1573-7373. ; 137:1, s. 111-118
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Children with diffuse intrinsic pontine glioma (DIPG) need new and more efficient treatments. They can be developed at relapse or at diagnosis, but therefore they must be combined with radiotherapy. Survival of children after recurrence and its predictors were studied to inform the possibility to design early phase clinical trials for DIPG at this stage. Among 142 DIPG patients treated between 1998 and 2014, 114 had biopsy-proven DIPG with histone H3 status available for 83. We defined as long survivors' patients who survived more than 3 months after relapse which corresponds to the minimal life expectancy requested for phase I/II trials. Factors influencing post-relapse survival were accordingly compared between short and long-term survivors after relapse. Fifty-seven percent of patients were considered long survivors and 70% of them had a Lansky Play Scale (LPS) above 50% at relapse. Patients who became steroids-independent after initial treatment for at least 2 months had better survival after relapse (3.7 versus 2.6 months, p = 0.001). LPS above 50% at relapse was correlated with better survival after relapse (3.8 versus 1.8 months, p < 0.001). Patients with H3.1 mutation survived longer after relapse (4.9 versus 2.7 months, p = 0.007). Patients who received a second radiotherapy at the time of relapse had an improved survival (7.5 versus 4 months, p = 0.001). In the two-way ANOVA analysis, steroid-independence and LPS predicted survival best and the type of histone H3 (H3.1 or H3.3) mutated did not improve prediction. Survival of many DIPG patients after relapse over 3 months would make possible to propose specific trials for this condition. Steroid-independence, H3 mutation status and LPS should be considered to predict eligibility.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Keyword

Brainstem glioma
H3K27M mutation
Midline infiltrative glioma
Steroid-independence

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view